Kairos Pharma, Ltd. (KAPA)
NYSEAMERICAN: KAPA · Real-Time Price · USD
0.6690
-0.0210 (-3.04%)
Jun 27, 2025, 4:00 PM - Market closed
Kairos Pharma Employees
As of December 31, 2024, Kairos Pharma had 4 total employees, including 1 full-time and 3 part-time employees.
Employees
4
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$885,500
Market Cap
11.27M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KAPA News
- 25 days ago - Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting - Business Wire
- 7 weeks ago - Kairos Pharma, Ltd. Announces Participation in the D. - Newsfile Corp
- 2 months ago - Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting - Business Wire
- 2 months ago - Kairos Pharma Ltd. Provides Letter to Stockholders - Business Wire
- 2 months ago - Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer - Business Wire
- 3 months ago - Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer - Business Wire
- 3 months ago - Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events - Business Wire
- 3 months ago - Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer - Business Wire